Holen Sie sich die Stockscreener-App
28.60
3.76%
-1.18
Schlusskurs vom Vortag:
$29.78
Offen:
$29.55
24-Stunden-Volumen:
607.00K
Relative Volume:
0.44
Marktkapitalisierung:
$3.03B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-150.70M
KGV:
-18.45
EPS:
-1.55
Netto-Cashflow:
$-125.67M
1W Leistung:
+4.64%
1M Leistung:
+31.80%
6M Leistung:
+99.17%
1J Leistung:
+6.15%
1-Tages-Spanne:
$28.60
$30.25
1-Wochen-Bereich:
$26.42
$30.25
52-Wochen-Spanne:
$10.60
$30.48
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Firmenname
Edgewise Therapeutics Inc
Sektor
Branche
Telefon
720-262-7002
Adresse
1715 38TH ST, BOULDER
Vergleichen Sie EWTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
28.60 | 3.15B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.40 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.13 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
815.55 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.91 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.33 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-25 | Eingeleitet | Goldman | Neutral |
| 2025-07-30 | Eingeleitet | Raymond James | Strong Buy |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-30 | Eingeleitet | Guggenheim | Buy |
| 2025-04-02 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-22 | Eingeleitet | Stifel | Hold |
| 2024-11-22 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-07 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2022-08-25 | Herabstufung | Goldman | Neutral → Sell |
| 2022-04-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-28 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Edgewise Therapeutics Inc Aktie (EWTX) Neueste Nachrichten
Retail Trends: Is Edgewise Therapeutics Inc trading at a discountJuly 2025 Institutional & Real-Time Volume Triggers - baoquankhu1.vn
Understanding the Setup: (EWTX) and Scalable Risk - Stock Traders Daily
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Eastern Progress
Edgewise Therapeutics, Inc. (EWTX) outlines priorities for 2026 - MSN
Is Edgewise Therapeutics (EWTX) Quietly Redefining Its Risk Profile With an Integrated Muscle-Heart Strategy? - Sahm
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 6.4%Time to Sell? - MarketBeat
Edgewise Therapeutics, Inc. (EWTX) Outlines Priorities For 2026 - Insider Monkey
14 Best Booming Stocks to Buy Right Now - Insider Monkey
A Look At Edgewise Therapeutics (EWTX) Valuation After Detailed 2026 Clinical Milestone Update - Sahm
Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX - TechStock²
Edgewise Therapeutics (NASDAQ:EWTX) Shares Up 7%Should You Buy? - MarketBeat
Technical Analysis: Is Edgewise Therapeutics Inc subject to activist investor interest2025 Analyst Calls & Risk Managed Investment Entry Signals - baoquankhu1.vn
Why Edgewise Therapeutics (EWTX) Is Up 8.8% After Mapping Its 2026 Rare-Disease Pipeline Priorities – And What's Next - Yahoo Finance
A Look At Edgewise Therapeutics (EWTX) Valuation After J P Morgan Clinical Pipeline Update - Yahoo Finance
Edgewise Therapeutics (EWTX) Stock Analysis: A 58% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 - Sahm
Edgewise Therapeutics provides corporate updates and highlights priorities for 2026 - marketscreener.com
Sectors Review: What analysts say about Edgewise Therapeutics Inc stock - baoquankhu1.vn
Why Edgewise Therapeutics Inc stock could benefit from AI revolutionPortfolio Update Report & Safe Entry Zone Tips - Bộ Nội Vụ
Can Edgewise Therapeutics Inc. stock double in next 5 yearsJuly 2025 Highlights & Daily Price Action Insights - ulpravda.ru
Can Edgewise Therapeutics Inc. stock continue upward trendWatch List & Low Risk Profit Maximizing Plans - ulpravda.ru
Momentum Shift: Is Edgewise Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Macro Moves & Growth Oriented Trade Recommendations - Улправда
Is Edgewise Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Macro Moves & Growth Oriented Trade Recommendations - Улправда
Edgewise Therapeutics rises 15.5% - MSN
Will Sure Ventures Plc (08F) stock extend growth storyRate Cut & Intraday High Probability Alerts - ulpravda.ru
Is Edgewise Therapeutics Inc. stock affected by interest rate hikesEarnings Performance Report & Free Verified High Yield Trade Plans - ulpravda.ru
How Edgewise Therapeutics Inc. stock compares to market leadersJuly 2025 Sentiment & Stock Portfolio Risk Control - Улправда
Will Edgewise Therapeutics Inc. stock remain a Wall Street favorite2025 Stock Rankings & Daily Growth Stock Investment Tips - Улправда
About Us | Laser Focus WorldEdgewise Therapeutics, Inc.Common Stock (Nasdaq:EWTX) Stock Quote - FinancialContent
Why Edgewise Therapeutics Inc. stock is seen as undervaluedJuly 2025 Earnings & Accurate Intraday Trading Signals - Улправда
Why Edgewise Therapeutics Inc. stock could benefit from AI revolutionSwing Trade & Technical Pattern Based Signals - Улправда
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events' - MSN
A Look At Edgewise Therapeutics (EWTX) Valuation After Positive CIRRUS HCM Phase 2 Trial Update - Sahm
Edgewise Therapeutics CEO to outline 2026 goals at JPMorgan event - Traders Union
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Exploring a 61.93% Upside Potential in Biotech - DirectorsTalk Interviews
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 - PR Newswire
Edgewise Therapeutics reports inducement grants as permitted by the Nasdaq Listing Rules - marketscreener.com
H.C. Wainwright Maintains a Buy on Edgewise Therapeutics (EWTX), Sets a $42 PT - MSN
Edgewise Therapeutics rises 20.3% - MSN
Edgewise Therapeutics Earnings Notes - Trefis
Aug Ideas: Can Edgewise Therapeutics Inc stock hit record highs againWeekly Investment Report & Momentum Based Trading Signals - moha.gov.vn
Why Edgewise Therapeutics stock rocked the market today - MSN
Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next - ts2.tech
Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge - ts2.tech
Edgewise rises on mid-stage trial data for heart disease therapy - MSN
Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX - ts2.tech
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownHere's What Happened - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Edgewise Therapeutics (EWTX) - The Globe and Mail
Valuation Update: Is Edgewise Therapeutics Inc stock a top pick in earnings seasonMarket Trend Report & Verified Entry Point Detection - moha.gov.vn
Finanzdaten der Edgewise Therapeutics Inc-Aktie (EWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.31%
2.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):